» Articles » PMID: 39849529

Emerging Targets of α-synuclein Spreading in α-synucleinopathies: a Review of Mechanistic Pathways and Interventions

Overview
Publisher Biomed Central
Date 2025 Jan 24
PMID 39849529
Authors
Affiliations
Soon will be listed here.
Abstract

α-Synucleinopathies constitute a spectrum of neurodegenerative disorders, including Parkinson's disease (PD), Lewy body dementia (LBD), Multiple System Atrophy (MSA), and Alzheimer's disease concurrent with LBD (AD-LBD). These disorders are unified by a pathological hallmark: aberrant misfolding and accumulation of α-synuclein (α-syn). This review delves into the pivotal role of α-syn, the key agent in α-synucleinopathy pathophysiology, and provides a survey of potential therapeutics that target cell-to-cell spread of pathologic α-syn. Recognizing the intricate complexity and multifactorial etiology of α-synucleinopathy, the review illuminates the potential of various membrane receptors, proteins, intercellular spreading pathways, and pathological agents for therapeutic interventions. While significant progress has been made in understanding α-synucleinopathy, the pursuit of efficacious treatments remains challenging. Several strategies involving decreasing α-syn production and aggregation, increasing α-syn degradation, lowering extracellular α-syn, and inhibiting cellular uptake of α-syn are presented. The paper underscores the necessity of meticulous and comprehensive investigations to advance our knowledge of α-synucleinopathy pathology and ultimately develop innovative therapeutic strategies for α-synucleinopathies.

References
1.
Papatheodorou I, Moreno P, Manning J, Munoz-Pomer Fuentes A, George N, Fexova S . Expression Atlas update: from tissues to single cells. Nucleic Acids Res. 2019; 48(D1):D77-D83. PMC: 7145605. DOI: 10.1093/nar/gkz947. View

2.
Buur L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, Kallunki P, Ditlevsen D . Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422. Mov Disord. 2024; 39(6):936-944. DOI: 10.1002/mds.29784. View

3.
Hoffmann A, Minakaki G, Menges S, Salvi R, Savitskiy S, Kazman A . Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose. Sci Rep. 2019; 9(1):544. PMC: 6345801. DOI: 10.1038/s41598-018-35811-8. View

4.
Fares M, Jagannath S, Lashuel H . Reverse engineering Lewy bodies: how far have we come and how far can we go?. Nat Rev Neurosci. 2021; 22(2):111-131. DOI: 10.1038/s41583-020-00416-6. View

5.
Meissner W, Pavy-Le Traon A, Foubert-Samier A, Galabova G, Galitzky M, Kutzelnigg A . A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. Mov Disord. 2020; 35(11):1957-1965. PMC: 7754431. DOI: 10.1002/mds.28218. View